NCT05987748

The Clock Thickens: Morning or Evening Training for the Treatment of NAFLD?

Name: Clinical Trial NCT05987748
Creator: Leiden University Medical Center
Keywords: Non-Alcoholic Fatty Liver Disease, Exercise training, behavioral, clinical trial, Netherlands

The Clock Thickens: Morning or Evening Training for the Treatment of NAFLD? (TikTac Study)

Leiden University Medical Center·ClinicalTrials.gov·behavioralNot yet recruiting

View on ClinicalTrials.gov →

Study focus

Disease/Condition: Non-Alcoholic Fatty Liver Disease
Drug/Device/Intervention: Exercise training
Study type: Interventional
Intervention type: behavioral

Sponsor & location

Primary sponsor: Leiden University Medical Center
Location: Leiden, Netherlands

Timeline & enrollment

Phase: N/A
Start date: Sep 01, 2023
End date: Sep 01, 2024
Enrollment: 40 participants

Primary outcome

Liver fat content

Summary

The goal of this clinical trial is to investigate the different effect of morning and evening exercise training in individuals with non-alcoholic fatty liver disease (NAFLD). The main question it aims to answer is:  • Is morning or evening exercise better for the treatment of NAFLD?  Participants will follow a supervised exercise training program for three months with either morning or evening training and the effect on liver health will be assessed. Researchers will compare the morning to the evening exercise group to see if one training timepoint is more effective than the other in reducing the amount of fat in the liver and improving liver health.

ICD-10 classifications

Alcoholic fatty liverAlcoholic liver disease, unspecifiedAlcoholic liver diseaseLiver disease, unspecifiedAlcoholic cirrhosis of liver

Data source

Registry: ClinicalTrials.gov
Trial ID: NCT05987748
Type: Non-Device Trial

About this record

Access comprehensive clinical trial information for NCT05987748 through Pure Global AI's free database. This phase not specified trial is sponsored by Leiden University Medical Center and is currently Not yet recruiting. The study focuses on Non-Alcoholic Fatty Liver Disease. Target enrollment is 40 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.